{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:24:19Z","timestamp":1754144659050,"version":"3.41.2"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.vhri.2025.101118","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T12:07:18Z","timestamp":1746274038000},"page":"101118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Effectiveness Analysis of Angiotensin Receptor Neprilysin Inhibitor Compared With Angiotensin-Converting Enzyme Inhibitor Among Patients With Heart Failure With Reduced Ejection Fraction in Malaysia"],"prefix":"10.1016","volume":"48","author":[{"given":"Wai Chee","family":"Kuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sit Wai","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siew Chin","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kok Han","family":"Chee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sazzli","family":"Kasim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja Ezman","family":"Raja Shariff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azmee","family":"Mohd Ghazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhamad Ali S.K.","family":"Abdul Kader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka Keat","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddesh","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Fox-Rushby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juman","family":"Dujaili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth Kwing-Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siew Li","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.vhri.2025.101118_bib1","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"7","key":"10.1016\/j.vhri.2025.101118_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288035","article-title":"Financial burden of heart failure in Malaysia: a perspective from the public healthcare system","volume":"18","author":"Ong","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vhri.2025.101118_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5334\/gh.1108","article-title":"Trends for readmission and mortality after heart failure hospitalisation in Malaysia, 2007 to 2016","volume":"17","author":"Lim","year":"2022","journal-title":"Glob Heart"},{"issue":"1","key":"10.1016\/j.vhri.2025.101118_bib4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s12872-020-01793-7","article-title":"Acute decompensated heart failure in a non cardiology tertiary referral centre, Sarawak General Hospital (SGH-HF)","volume":"20","author":"Ling","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.vhri.2025.101118_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12872-018-0815-3","article-title":"Cost-of-illness studies in heart failure: a systematic review 2004-2016","volume":"18","author":"Lesyuk","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.vhri.2025.101118_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12913-015-0925-x","article-title":"Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures","volume":"15","author":"Song","year":"2015","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"10.1016\/j.vhri.2025.101118_bib7","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/ehf2.13992","article-title":"Patient profiles on outcomes in patients hospitalized for heart failure: a 10-year history of the Malaysian population","volume":"9","author":"Mohd Ghazi","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10.1016\/j.vhri.2025.101118_bib8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11136-024-03818-6","article-title":"Trajectory of health-related quality of life during and after hospitalisation due to worsening of heart failure","volume":"34","author":"Kuan","year":"2024","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.vhri.2025.101118_bib9","first-page":"52","article-title":"Critical factors in quality of life: a qualitative explorations into the experiences of Malaysian with heart failure","volume":"16","author":"Mohamed","year":"2020","journal-title":"Malays J Med Health Sci"},{"issue":"8","key":"10.1016\/j.vhri.2025.101118_bib10","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s11136-024-03674-4","article-title":"Examining health-related quality of life in ambulatory adult patients with chronic heart failure: insights from Malaysia using EQ-5D-5L","volume":"33","author":"Tan","year":"2024","journal-title":"Qual Life Res"},{"issue":"18","key":"10.1016\/j.vhri.2025.101118_bib11","first-page":"e895","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"year":"2023","series-title":"Clinical Practice Guidelines on Management of Heart Failure","key":"10.1016\/j.vhri.2025.101118_bib12"},{"issue":"36","key":"10.1016\/j.vhri.2025.101118_bib13","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.vhri.2025.101118_bib14","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin Inhibition versus enalapril in Heart Failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vhri.2025.101118_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003430","article-title":"Health-related quality of life outcomes in PARADIGM-HF","volume":"10","author":"Lewis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.vhri.2025.101118_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.922721","article-title":"Effects of sacubitril\/valsartan on life quality in chronic heart failure: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Song","year":"2022","journal-title":"Front Cardiovasc Med"},{"author":"Fong","key":"10.1016\/j.vhri.2025.101118_bib18"},{"issue":"1","key":"10.1016\/j.vhri.2025.101118_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12872-023-03374-w","article-title":"Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.vhri.2025.101118_bib22","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12872-021-02145-9","article-title":"Real-world experience of angiotensin receptor\/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis","volume":"21","author":"Rattanavipanon","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"issue":"11","key":"10.1016\/j.vhri.2025.101118_bib23","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jchf.2019.05.016","article-title":"Association between Sacubitril\/Valsartan initiation and health status outcomes in heart failure with reduced ejection fraction","volume":"7","author":"Khariton","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.vhri.2025.101118_bib24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00392-022-02124-w","article-title":"Real-world comparative effectiveness of ARNI versus ACEi\/ARB in HF with reduced or mildly reduced ejection fraction","volume":"112","author":"Fu","year":"2023","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"10.1016\/j.vhri.2025.101118_bib25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/08971900221087106","article-title":"Cost-effectiveness of Sacubitril\u2013Valsartan compared to angiotensin-converting enzyme inhibitors in patients with heart failure with reduced ejection fraction","volume":"36","author":"Febrinasari","year":"2022","journal-title":"J Pharm Pract"},{"issue":"5","key":"10.1016\/j.vhri.2025.101118_bib26","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s10741-020-09956-6","article-title":"Cost-effectiveness analyses of sacubitril-valsartan for heart failure","volume":"26","author":"Liu","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.vhri.2025.101118_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.919974","article-title":"Cost effectiveness analyses of pharmacological treatments in heart failure","volume":"13","author":"Lim","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.vhri.2025.101118_bib28","first-page":"168","article-title":"Cost-effectiveness of Sacubitril\/Valsartan compared with enalapril in patients with heart failure with reduced ejection fraction: a systematic review","volume":"17","author":"Rezapour","year":"2022","journal-title":"J Tehran Univ Heart Cent"},{"issue":"2","key":"10.1016\/j.vhri.2025.101118_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ehf2.12036","article-title":"Heart failure in Southeast Asia: facts and numbers","volume":"2","author":"Lam","year":"2015","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.vhri.2025.101118_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.971592","article-title":"Cost analysis of chronic heart failure management in Malaysia: a multi-centred retrospective study","volume":"9","author":"Ong","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2025.101118_bib32","first-page":"863","article-title":"Suboptimal guideline-directed medical therapy and prognosis in patients with heart failure and reduced ejection fraction: the SMYRNA Study","volume":"44","author":"Kocabas","year":"2023","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.vhri.2025.101118_bib33","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.jchf.2024.05.026","article-title":"Optimal medical therapy and outcomes among patients with chronic heart failure with reduced ejection fraction","volume":"12","author":"Rao","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"8","key":"10.1016\/j.vhri.2025.101118_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0305257","article-title":"Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction","volume":"19","author":"Tan","year":"2024","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.vhri.2025.101118_bib35","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jval.2023.05.011","article-title":"Economic evaluations of guideline-directed medical therapies for heart failure with reduced ejection fraction: a systematic review","volume":"26","author":"Kuan","year":"2023","journal-title":"Value Health"},{"issue":"14","key":"10.1016\/j.vhri.2025.101118_bib36","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028782","article-title":"Individual trajectories of health status during the first year of discharge from hospitalization for heart failure and their associations with death in the following years","volume":"12","author":"Zhang","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"36","key":"10.1016\/j.vhri.2025.101118_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8360","article-title":"Review of guidelines for good practice in decision-analytic modelling in health technology assessment","volume":"8","author":"Philips","year":"2004","journal-title":"Health Technol Assess"},{"issue":"6","key":"10.1016\/j.vhri.2025.101118_bib38","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.vhri.2025.101118_bib39","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3","volume":"15","author":"Siebert","year":"2012","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2025.101118_bib41","first-page":"3","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"7","author":"Husereau","year":"2022","journal-title":"MDM Policy Pract"},{"issue":"2","key":"10.1016\/j.vhri.2025.101118_bib42","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ehf2.14608","article-title":"Characteristics of patients admitted with heart failure: insights from the first Malaysian Heart Failure Registry","volume":"11","author":"Wan Ahmad","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.vhri.2025.101118_bib43","article-title":"Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.vhri.2025.101118_bib44","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1002\/ehf2.13313","article-title":"SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis","volume":"8","author":"Yan","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.vhri.2025.101118_bib48","series-title":"Acute heart failure \u2013 the \u2018real\u2019 Malaysian experience: an observational study from a single non-cardiac centre. Proceedings of Singapore Healthcare","first-page":"218","volume":"30","author":"Raja Shariff","year":"2021"},{"issue":"1","key":"10.1016\/j.vhri.2025.101118_bib46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.vhri.2025.101118_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.vhri.2025.101118_bib49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40273-019-00859-5","article-title":"Potential bias associated with modeling the effectiveness of healthcare interventions in reducing mortality using an overall hazard ratio","volume":"38","author":"Alarid-Escudero","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vhri.2025.101118_bib50","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/13696998.2024.2337563","article-title":"Validity and measurement equivalence of EQ-5D-5L questionnaire among heart failure patients in Malaysia: a cohort study","volume":"27","author":"Kuan","year":"2024","journal-title":"J Med Econ"},{"issue":"6","key":"10.1016\/j.vhri.2025.101118_bib51","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of Sacubitril\/Valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"16","key":"10.1016\/j.vhri.2025.101118_bib53","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021566","article-title":"Research priorities in the secondary prevention of atrial fibrillation: a National Heart, Lung, and Blood Institute virtual workshop report","volume":"10","author":"Benjamin","year":"2021","journal-title":"J Am Heart Assoc"},{"author":"Calder\u00f3n","key":"10.1016\/j.vhri.2025.101118_bib56"},{"issue":"12","key":"10.1016\/j.vhri.2025.101118_bib57","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006539","article-title":"Sex-related differences in heart failure with preserved ejection fraction","volume":"12","author":"Dewan","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10.1016\/j.vhri.2025.101118_bib58","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002554","article-title":"Comparison of the efficacy and safety of different ACE inhibitors in patients with chronic heart failure: a PRISMA-compliant network meta-analysis","volume":"95","author":"Sun","year":"2016","journal-title":"Med (Baltim)"},{"issue":"2","key":"10.1016\/j.vhri.2025.101118_bib59","doi-asserted-by":"crossref","first-page":"102","DOI":"10.7326\/0003-4819-141-2-200407200-00008","article-title":"Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?","volume":"141","author":"Pilote","year":"2004","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.vhri.2025.101118_bib60","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/0272989X15575286","article-title":"Estimating the expected value of sample information using the probabilistic sensitivity analysis sample: a fast, nonparametric regression-based method","volume":"35","author":"Strong","year":"2015","journal-title":"Med Decis Mak"},{"issue":"1","key":"10.1016\/j.vhri.2025.101118_bib61","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.007993","article-title":"Perks and pitfalls of performance-linked reimbursement for novel drugs: the case of Sacubitril-Valsartan","volume":"15","author":"Sandhu","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.vhri.2025.101118_bib62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.vhri.2022.02.003","article-title":"Stakeholders\u2019 views on patient access schemes in Malaysia","volume":"31","author":"Thanimalai","year":"2022","journal-title":"Value Health Reg Issues"},{"issue":"4","key":"10.1016\/j.vhri.2025.101118_bib63","first-page":"590","article-title":"Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction","volume":"7","author":"Bello","year":"2014","journal-title":"Circ"},{"issue":"8","key":"10.1016\/j.vhri.2025.101118_bib64","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.vhri.2025.101118_bib65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/eurheartj\/eht278","article-title":"Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden","volume":"35","author":"Barasa","year":"2014","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.vhri.2025.101118_bib66","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jchf.2022.01.021","article-title":"Trends in HF hospitalizations among young adults in the United States from 2004 to 2018","volume":"10","author":"Jain","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"14","key":"10.1016\/j.vhri.2025.101118_bib67","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/CIRCULATIONAHA.116.021859","article-title":"Return to the workforce after first hospitalization for heart failure","volume":"134","author":"R\u00f8rth","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.vhri.2025.101118_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1195124","article-title":"Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia","volume":"14","author":"Ong","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925000433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925000433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:28:42Z","timestamp":1752611322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109925000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":59,"alternative-id":["S2212109925000433"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101118","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Angiotensin Receptor Neprilysin Inhibitor Compared With Angiotensin-Converting Enzyme Inhibitor Among Patients With Heart Failure With Reduced Ejection Fraction in Malaysia","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101118"}}